Loading...
XNASVXRT
Market cap168mUSD
Jan 17, Last price  
0.74USD
1D
-0.20%
1Q
-9.72%
Jan 2017
-94.53%
Name

Vaxart Inc

Chart & Performance

D1W1MN
XNAS:VXRT chart
P/E
—
P/S
22.81
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
87.10%
Rev. gr., 5y
12.15%
Revenues
7m
+6,796.26%
142,183,000108,055,00089,868,0000010,489,00035,005,00014,838,00033,600,00068,700,00024,600,0009,300,0008,900,0005,839,0004,159,0009,862,0004,046,000892,000107,0007,379,000
Net income
-82m
L-23.47%
-50,390,000-128,449,000-58,703,00047,069,000-18,738,000-18,727,000878,000-4,531,000-8,900,000-11,000,000-19,100,000-25,400,000-29,400,000-12,460,000-18,007,000-18,645,000-32,220,000-70,470,000-107,758,000-82,465,000
CFO
-70m
L-25.67%
8,738,000-89,714,000-43,912,000-26,744,000-18,901,0006,217,00039,932,000-15,166,000-13,900,000-3,300,000-9,600,000-14,100,000-30,000,000-10,040,000-14,548,000-13,090,000-23,750,000-59,832,000-94,779,000-70,453,000
Dividend
Nov 09, 20126.648 USD/sh
Earnings
Feb 26, 2025

Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
URL
https://vaxart.com/
IPO date
Mar 17, 1980
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
7,379
6,796.26%
107
-88.00%
Cost of revenue
158,868
113,707
Unusual Expense (Income)
NOPBT
(151,489)
(113,600)
NOPBT Margin
Operating Taxes
261
67
Tax Rate
NOPAT
(151,750)
(113,667)
Net income
(82,465)
-23.47%
(107,758)
52.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,664
17,237
BB yield
-17.68%
-14.05%
Debt
Debt current
6,506
2,228
Long-term debt
40,096
41,182
Deferred revenue
Other long-term liabilities
293
5,852
Net debt
6,889
(50,307)
Cash flow
Cash from operating activities
(70,453)
(94,779)
CAPEX
(1,871)
(9,601)
Cash from investing activities
43,952
(20,415)
Cash from financing activities
15,243
17,462
FCF
(147,021)
(135,198)
Balance
Cash
39,713
93,717
Long term investments
Excess cash
39,344
93,712
Stockholders' equity
(409,560)
(327,395)
Invested Capital
495,230
465,549
ROIC
ROCE
EV
Common stock shares outstanding
144,820
127,684
Price
0.57
-40.39%
0.96
-84.67%
Market cap
82,953
-32.39%
122,691
-83.89%
EV
89,842
72,384
EBITDA
(142,865)
(107,795)
EV/EBITDA
Interest
1,447
1,305
Interest/NOPBT